



## Clinical trial results:

### A Randomised, Double-blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Topically Applied DGLA Cream in Patients with Mild to Moderate Atopic Dermatitis

#### Summary

EudraCT number	2012-003739-44
Trial protocol	FI SE HU DK BG
Global end of trial date	13 January 2014

#### Results information

Result version number	v2 (current)
This version publication date	23 July 2022
First version publication date	25 April 2022
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Correction of full data set

#### Trial information

##### Trial identification

Sponsor protocol code	DS107E-02
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Dignity Sciences Limited
Sponsor organisation address	Trintech Building, South County Business Park, Dublin, Ireland, Dublin 18
Public contact	Study Director, Dignity Sciences Limited, +353 1 2933 590, dsbiopharma.regulatory@dsbiopharma.com
Scientific contact	Study Director, Dignity Sciences Limited, +353 1 2933 590, dsbiopharma.regulatory@dsbiopharma.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 June 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 January 2014
Global end of trial reached?	Yes
Global end of trial date	13 January 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Primary: To compare the effectiveness of three doses of topically applied DGLA cream, versus placebo, in the treatment of adult patients with mild to moderate atopic dermatitis.

Secondary: To assess the safety, tolerability and the bioavailability of three doses of topically applied DGLA cream versus placebo, in patients with mild to moderate atopic dermatitis.

Protection of trial subjects:

The study was managed and conducted according to the World Medical Association Declaration of Helsinki 1964, the latest International Conference on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirement(s) (specifically the principles of GCP in ICH topic E6, as laid down by the Commission Directive 2005/28/EC and in accordance with applicable local laws and guidelines).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 January 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 13
Country: Number of subjects enrolled	Finland: 49
Country: Number of subjects enrolled	Hungary: 89
Country: Number of subjects enrolled	Bulgaria: 52
Worldwide total number of subjects	203
EEA total number of subjects	203

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	193
From 65 to 84 years	10
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This was a randomized, placebo-controlled, double-blind, parallel group, multi-centre Phase II study.

### Pre-assignment

Screening details:

The study consisted of a wash-out period of 14 days, for patients who were currently receiving treatment for their atopic dermatitis at the Screening visit; a 28 day treatment period and a 7 day follow up period.

### Period 1

Period 1 title	Overall Study Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	DS107E DGLA 0.1% Cream

Arm description:

DS107E DGLA 0.1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Arm type	Experimental
Investigational medicinal product name	DS107 Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

DS107E DGLA 0.1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

<b>Arm title</b>	DS107E DGLA 1% cream
------------------	----------------------

Arm description:

DS107E DGLA 1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Arm type	Experimental
Investigational medicinal product name	DS107 Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

DS107E DGLA 1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

<b>Arm title</b>	DS107E DGLA 5% cream
------------------	----------------------

Arm description:

DS107E DGLA 5% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	DS107 Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

DS107E DGLA 5% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

<b>Arm title</b>	DS107E Placebo cream
------------------	----------------------

Arm description:

DS107E Placebo cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Arm type	Placebo
Investigational medicinal product name	Matching DS107 Placebo Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

DS107E Placebo cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

<b>Number of subjects in period 1<sup>[1]</sup></b>	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream
Started	49	52	51
Completed	46	49	48
Not completed	3	3	3
Consent withdrawn by subject	-	-	1
Adverse event, non-fatal	-	-	1
Lost to follow-up	2	-	-
Disease Progression	1	2	-
Protocol deviation	-	1	1

<b>Number of subjects in period 1<sup>[1]</sup></b>	DS107E Placebo cream
Started	50
Completed	47
Not completed	3
Consent withdrawn by subject	1
Adverse event, non-fatal	-
Lost to follow-up	-
Disease Progression	1
Protocol deviation	1

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 203 subjects were enrolled in the Total Population of the study, however, one subject did not receive any treatment and so was excluded from the ITT Population.

## Baseline characteristics

### Reporting groups

Reporting group title	DS107E DGLA 0.1% Cream
Reporting group description: DS107E DGLA 0.1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E DGLA 1% cream
Reporting group description: DS107E DGLA 1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E DGLA 5% cream
Reporting group description: DS107E DGLA 5% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E Placebo cream
Reporting group description: DS107E Placebo cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	

Reporting group values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream
Number of subjects	49	52	51
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	46	50	47
From 65-84 years	3	2	4
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	35.7	34.2	34.5
standard deviation	± 15.4	± 14.6	± 16.6
Gender categorical Units: Subjects			
Female	27	37	36
Male	22	15	15
Ethnicity Units: Subjects			
Caucasian	48	52	51
Other	1	0	0

Reporting group values	DS107E Placebo cream	Total	
Number of subjects	50	202	

Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	49	192	
From 65-84 years	1	10	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	34.5		
standard deviation	± 13.4	-	
Gender categorical			
Units: Subjects			
Female	36	136	
Male	14	66	
Ethnicity			
Units: Subjects			
Caucasian	50	201	
Other	0	1	

## End points

### End points reporting groups

Reporting group title	DS107E DGLA 0.1% Cream
Reporting group description: DS107E DGLA 0.1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E DGLA 1% cream
Reporting group description: DS107E DGLA 1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E DGLA 5% cream
Reporting group description: DS107E DGLA 5% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	
Reporting group title	DS107E Placebo cream
Reporting group description: DS107E Placebo cream applied topically to all affected or commonly affected areas twice-daily for 28 days.	

### Primary: Change in modified Eczema Area and Severity Index (mEASI) from baseline (Day 0/start of IMP treatment) to 28 days (end of treatment) to evaluate the efficacy of three doses of topically applied DGLA cream in comparison to placebo.

End point title	Change in modified Eczema Area and Severity Index (mEASI) from baseline (Day 0/start of IMP treatment) to 28 days (end of treatment) to evaluate the efficacy of three doses of topically applied DGLA cream in comparison to placebo.
End point description: Change in modified Eczema Area and Severity Index (mEASI) from baseline (Day 0/start of IMP treatment) to 28 days (end of treatment) to evaluate the efficacy of three doses of topically applied DGLA cream in comparison to placebo.	
End point type	Primary
End point timeframe: Up to 28 days.	

End point values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: mEASI Scores				
arithmetic mean (standard deviation)	-1.86 (± 5.34)	-2.87 (± 4.23)	-2.83 (± 4.68)	-3.96 (± 7.11)

### Statistical analyses

Statistical analysis title	DGLA V Placebo
Comparison groups	DS107E DGLA 0.1% Cream v DS107E DGLA 1% cream v

	DS107E DGLA 5% cream v DS107E Placebo cream
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3086
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	0.86534534
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8064781
upper limit	2.53716879

---

**Secondary: Change in modified Eczema Area and Severity Index (mEASI) from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14 and 21 days.**

---

End point title	Change in modified Eczema Area and Severity Index (mEASI) from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14 and 21 days.
End point description:	
End point type	Secondary
End point timeframe:	
Up to 21 days.	

---

End point values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: mEASI Scores				
arithmetic mean (standard deviation)				
Baseline to Day 7	-0.82 (± 2.84)	-1.09 (± 3.31)	-0.57 (± 2.53)	-0.03 (± 3.73)
Baseline to Day 14	-1.59 (± 3.97)	-1.89 (± 3.59)	-2.29 (± 2.84)	-2.37 (± 4.29)
Baseline to Day 21	-2.31 (± 3.87)	-2.49 (± 3.83)	-2.83 (± 3.31)	-3.98 (± 4.81)

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Change in Investigator's Global Assessment (IGA) score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.**

---

End point title	Change in Investigator's Global Assessment (IGA) score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------

---

End point description:

Change in Investigator's Global Assessment (IGA) score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 28 days.

End point values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: IGA Scores				
arithmetic mean (standard deviation)				
Baseline to Day 7	-0.2 (± 0.5)	-0.1 (± 0.6)	-0.0 (± 0.5)	0.0 (± 0.4)
Baseline to Day 14	-0.3 (± 0.7)	-0.2 (± 0.7)	-0.3 (± 0.6)	-0.2 (± 0.6)
Baseline to Day 21	-0.4 (± 0.8)	-0.3 (± 0.8)	-0.3 (± 0.5)	-0.5 (± 0.7)
Baseline to Day 28	-0.4 (± 1.0)	-0.6 (± 0.9)	-0.5 (± 0.8)	-0.3 (± 1.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change in the patient's Visual Analogue Scale (VAS) pruritus score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point title	Change in the patient's Visual Analogue Scale (VAS) pruritus score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change in the patient's VAS pruritus score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 28 days.

End point values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: VAS Pruritus Scores				
arithmetic mean (standard deviation)				
Baseline to Day 7	-5.7 (± 19.8)	-7.2 (± 18.2)	-6.9 (± 17.7)	-1.5 (± 21.2)
Baseline to Day 14	-7.0 (± 19.8)	-11.1 (± 21.4)	-12.3 (± 17.7)	-10.8 (± 22.1)
Baseline to Day 21	-10.4 (± 24.2)	-15.1 (± 26.1)	-17.5 (± 21.9)	-19.6 (± 24.0)
Baseline to Day 28	-15.0 (± 25.7)	-15.9 (± 26.9)	-20.0 (± 22.9)	-18.1 (± 30.4)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change in the Patient Orientated Eczema Measure (POEM) from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point title	Change in the Patient Orientated Eczema Measure (POEM) from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change in the POEM from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 28 days.

End point values	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: POEM Scores				
arithmetic mean (standard deviation)				
Baseline to Day 7	-1.5 (± 4.7)	-2.9 (± 4.7)	-2.1 (± 5.1)	-1.5 (± 3.4)
Baseline to Day 14	-2.8 (± 5.7)	-3.6 (± 5.0)	-4.6 (± 4.6)	-3.4 (± 5.2)
Baseline to Day 21	-3.9 (± 6.8)	-4.9 (± 5.7)	-5.1 (± 5.6)	-6.4 (± 5.3)
Baseline to Day 28	-3.5 (± 6.7)	-4.8 (± 6.8)	-5.0 (± 6.2)	-5.5 (± 7.2)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change in the Dermatology Life Quality Index (DLQI) score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point title	Change in the Dermatology Life Quality Index (DLQI) score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change in the DLQI score from screening (Visit 1) to baseline (Visit 2) and from baseline to 7, 14, 21 and 28 days.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 28 days.

<b>End point values</b>	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream	DS107E Placebo cream
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	52	51	50
Units: DLQI Scores				
arithmetic mean (standard deviation)				
Baseline to Day 7	-0.9 (± 2.4)	-1.8 (± 4.9)	-1.1 (± 3.7)	-1.2 (± 3.3)
Baseline to Day 14	-1.8 (± 3.5)	-2.5 (± 4.4)	-3.2 (± 3.6)	-2.3 (± 5.1)
Baseline to Day 21	-2.7 (± 4.2)	-4.0 (± 4.7)	-3.8 (± 3.9)	-4.2 (± 4.4)
Baseline to Day 28	-2.4 (± 4.3)	-4.2 (± 5.5)	-3.6 (± 4.8)	-3.5 (± 5.9)

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 35 days

Adverse event reporting additional description:

An adverse event (AE) is any undesirable experience occurring to a patient that has signed the ICF, whether or not considered related to the investigational IMP(s). All Adverse Events must be recorded in the case report form, defining relationship to IMP and severity.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

### Reporting groups

Reporting group title	DS107E DGLA 0.1% Cream
-----------------------	------------------------

Reporting group description:

DS107E DGLA 0.1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Reporting group title	DS107E DGLA 1% cream
-----------------------	----------------------

Reporting group description:

DS107E DGLA 1% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Reporting group title	DS107E DGLA 5% cream
-----------------------	----------------------

Reporting group description:

DS107E DGLA 5% cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Reporting group title	DS107E Placebo cream
-----------------------	----------------------

Reporting group description:

DS107E Placebo cream applied topically to all affected or commonly affected areas twice-daily for 28 days.

Serious adverse events	DS107E DGLA 0.1% Cream	DS107E DGLA 1% cream	DS107E DGLA 5% cream
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	DS107E Placebo cream		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	<b>DS107E DGLA 0.1% Cream</b>	<b>DS107E DGLA 1% cream</b>	<b>DS107E DGLA 5% cream</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 49 (57.14%)	27 / 52 (51.92%)	30 / 51 (58.82%)
<b>Vascular disorders</b>			
Haemorrhage			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
<b>General disorders and administration site conditions</b>			
Application site dryness			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Application site erythema			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	2 / 51 (3.92%)
occurrences (all)	0	1	2
Application site irritation			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	4	0	0
Application site pain			
subjects affected / exposed	1 / 49 (2.04%)	5 / 52 (9.62%)	4 / 51 (7.84%)
occurrences (all)	1	8	4
Application site pruritus			
subjects affected / exposed	1 / 49 (2.04%)	3 / 52 (5.77%)	1 / 51 (1.96%)
occurrences (all)	1	6	1
Application site reaction			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Application site urticaria			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
<b>Inflammation</b>			

subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Nodule subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 1	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	1 / 51 (1.96%) 2
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Epistaxis subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 2	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	3 / 51 (5.88%) 3
Rhinitis allergic subjects affected / exposed occurrences (all)	1 / 49 (2.04%) 2	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 52 (1.92%) 1	1 / 51 (1.96%) 1
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Investigations Blood cholesterol increased subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0

Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	4 / 51 (7.84%)
occurrences (all)	0	0	4
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Excoriation			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Burning sensation			
subjects affected / exposed	1 / 49 (2.04%)	1 / 52 (1.92%)	1 / 51 (1.96%)
occurrences (all)	2	1	1
Headache			
subjects affected / exposed	4 / 49 (8.16%)	2 / 52 (3.85%)	2 / 51 (3.92%)
occurrences (all)	4	2	2
Hyperaesthesia			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Migraine			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	2

Syncope subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	1 / 52 (1.92%) 1	0 / 51 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Eye disorders Conjunctivitis subjects affected / exposed occurrences (all)  Eye pain subjects affected / exposed occurrences (all)  Eye swelling subjects affected / exposed occurrences (all)  Eyelid exfoliation subjects affected / exposed occurrences (all)  Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0	1 / 52 (1.92%) 1  0 / 52 (0.00%) 0  0 / 52 (0.00%) 0  0 / 52 (0.00%) 0  0 / 52 (0.00%) 0	0 / 51 (0.00%) 0  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)  Abdominal pain upper subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Oral pain	0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  1 / 49 (2.04%) 1  0 / 49 (0.00%) 0	0 / 52 (0.00%) 0  1 / 52 (1.92%) 1  1 / 52 (1.92%) 1  0 / 52 (0.00%) 0	0 / 51 (0.00%) 0  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1

subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Regurgitation			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	2 / 49 (4.08%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Blister			
subjects affected / exposed	2 / 49 (4.08%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Dermatitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	2 / 51 (3.92%)
occurrences (all)	0	0	2
Dermatitis atopic			
subjects affected / exposed	5 / 49 (10.20%)	4 / 52 (7.69%)	2 / 51 (3.92%)
occurrences (all)	5	4	2
Dermatitis contact			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	3 / 49 (6.12%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	9	0	1
Eczema			
subjects affected / exposed	1 / 49 (2.04%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	1	2	0
Eczema weeping			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	3 / 49 (6.12%)	3 / 52 (5.77%)	8 / 51 (15.69%)
occurrences (all)	12	3	12

Pain of skin			
subjects affected / exposed	2 / 49 (4.08%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Papule			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	7 / 49 (14.29%)	8 / 52 (15.38%)	10 / 51 (19.61%)
occurrences (all)	17	12	19
Rash			
subjects affected / exposed	2 / 49 (4.08%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	2	0	1
Rash pruritic			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Scab			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Skin burning sensation			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	3	0	1
Skin exfoliation			
subjects affected / exposed	0 / 49 (0.00%)	3 / 52 (5.77%)	2 / 51 (3.92%)
occurrences (all)	0	3	3
Skin fissures			
subjects affected / exposed	2 / 49 (4.08%)	1 / 52 (1.92%)	1 / 51 (1.96%)
occurrences (all)	5	1	1
Skin irritation			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Skin tightness			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Sunburn			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0

Urticaria subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	1 / 51 (1.96%) 1
Renal and urinary disorders Urogenital disorder subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0	0 / 52 (0.00%) 0	0 / 51 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Back pain subjects affected / exposed occurrences (all)  Bursitis subjects affected / exposed occurrences (all)  Neck pain subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0  1 / 49 (2.04%) 1  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0	0 / 52 (0.00%) 0  1 / 52 (1.92%) 2  0 / 52 (0.00%) 0  1 / 52 (1.92%) 1	1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0
Infections and infestations Cystitis subjects affected / exposed occurrences (all)  Gastroenteritis subjects affected / exposed occurrences (all)  Herpes simplex subjects affected / exposed occurrences (all)  Herpes virus infection subjects affected / exposed occurrences (all)  Impetigo subjects affected / exposed occurrences (all)	0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  0 / 49 (0.00%) 0  1 / 49 (2.04%) 1	1 / 52 (1.92%) 1  3 / 52 (5.77%) 3  0 / 52 (0.00%) 0  1 / 52 (1.92%) 1  0 / 52 (0.00%) 0	0 / 51 (0.00%) 0  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0

Influenza			
subjects affected / exposed	1 / 49 (2.04%)	2 / 52 (3.85%)	1 / 51 (1.96%)
occurrences (all)	1	2	1
Nasopharyngitis			
subjects affected / exposed	0 / 49 (0.00%)	2 / 52 (3.85%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Pharyngitis			
subjects affected / exposed	2 / 49 (4.08%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Sinusitis			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 49 (4.08%)	1 / 52 (1.92%)	1 / 51 (1.96%)
occurrences (all)	2	1	1
Vaginal infection			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
vaginitis bacterial			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	DS107E Placebo cream		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 50 (48.00%)		
Vascular disorders			
Haemorrhage			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			

Application site dryness subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Application site erythema subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Application site irritation subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Application site pain subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2		
Application site pruritus subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 3		
Application site reaction subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 2		
Application site urticaria subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Inflammation subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Nodule subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Pyrexia subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1		
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences (all)	2		
Rhinitis allergic			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Investigations			
Blood cholesterol increased			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Lymphocyte count increased			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Neutrophil count increased			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Platelet count decreased			

subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Injury, poisoning and procedural complications			
Excoriation			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Thermal burn			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Nervous system disorders			
Burning sensation			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	7 / 50 (14.00%)		
occurrences (all)	11		
Hyperaesthesia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Eye disorders			
Conjunctivitis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Eye pain			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		

Eye swelling subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Eyelid exfoliation subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1		
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Diarrhoea subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Nausea subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Oral pain subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Regurgitation subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Vomiting subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Blister			

subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Dermatitis</b>			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Dermatitis atopic</b>			
subjects affected / exposed	4 / 50 (8.00%)		
occurrences (all)	4		
<b>Dermatitis contact</b>			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Dry skin</b>			
subjects affected / exposed	4 / 50 (8.00%)		
occurrences (all)	5		
<b>Eczema</b>			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Eczema weeping</b>			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	2		
<b>Erythema</b>			
subjects affected / exposed	6 / 50 (12.00%)		
occurrences (all)	8		
<b>Pain of skin</b>			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Papule</b>			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
<b>Pruritus</b>			
subjects affected / exposed	7 / 50 (14.00%)		
occurrences (all)	10		
<b>Rash</b>			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
<b>Rash pruritic</b>			

subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Scab			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Skin burning sensation			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Skin exfoliation			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Skin fissures			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Skin irritation			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Skin tightness			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Sunburn			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Urogenital disorder			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Back pain			

subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Bursitis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Cystitis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Herpes simplex			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	2		
Herpes virus infection			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Impetigo			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences (all)	6		
Pharyngitis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	0 / 50 (0.00%)		
occurrences (all)	0		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1		
Vaginal infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
vaginitis bacterial subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		
Viral infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 April 2013	<ul style="list-style-type: none"><li>• Personnel and CRO name changes.</li><li>• Guidelines around pregnancy and contraception updated.</li><li>• Clarification of washout period.</li><li>• Two medications excluded from the restricted concomitant medication list.</li><li>• Reporting of adverse events. Change of responsible Party.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported